The estimated Net Worth of Jeffrey W. Runge is at least 6.13 千$ dollars as of 1 June 2021. Jeffrey Runge owns over 10,000 units of ADiTx Therapeutics stock worth over 6,125$ and over the last 4 years he sold ADTX stock worth over 0$. In addition, he makes 0$ as Independent Director at ADiTx Therapeutics.
Sign up
Jeffrey Runge ADTX stock SEC Form 4 insiders trading
Jeffrey has made over 1 trades of the ADiTx Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of ADTX stock worth 29,300$ on 1 June 2021.
The largest trade he's ever made was buying 10,000 units of ADiTx Therapeutics stock on 1 June 2021 worth over 29,300$. On average, Jeffrey trades about 2,500 units every 0 days since 2020. As of 1 June 2021 he still owns at least 12,500 units of ADiTx Therapeutics stock.
You can see the complete history of Jeffrey Runge stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Jeffrey Runge biography
Jeffrey Runge is the Independent Director at ADiTx Therapeutics.
What's Jeffrey Runge's mailing address?
Jeffrey's mailing address filed with the SEC is C/O ADITXT, INC., 737 N. FIFTH STREET, SUITE 200, RICHMOND, VA, 23219.
Insiders trading at ADiTx Therapeutics
Over the last 4 years, insiders at ADiTx Therapeutics have traded over 691,184$ worth of ADiTx Therapeutics stock and bought 24,613 units worth 89,662$ . The most active insiders traders include Paribas Securities Corp Bnp、Corinne Pankovcin、Jeffrey W. Runge. On average, ADiTx Therapeutics executives and independent directors trade stock every 93 days with the average trade being worth of 2,473$. The most recent stock trade was executed by Paribas Securities Corp Bnp on 6 September 2023, trading 20,800 units of ADTX stock currently worth 691,184$.
What does ADiTx Therapeutics do?
Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune reprogramming and monitoring. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.
What does ADiTx Therapeutics's logo look like?
Complete history of Jeffrey Runge stock trades at ADiTx Therapeutics
ADiTx Therapeutics executives and stock owners
ADiTx Therapeutics executives and other stock owners filed with the SEC include:
-
Amro Albanna,
Chairman of the Board, President, Chief Executive Officer -
Corinne D. Pankovcin CPA, CPA, M.B.A.,
Pres -
Amro A. Albanna,
Co-Founder, Chairman & CEO -
Dr. Shahrokh Shabahang D.D.S., M.S., Ph.D.,
Co-Founder, Chief Innovation Officer, Sec. & Director -
Shahrokh Shabahang,
Chief Innovation Officer, Director -
Jeffrey Runge,
Independent Director -
Namvar Kiaie,
Independent Director -
Brian Brady,
Independent Director -
Laura Anthony,
Independent Director -
Rowena Albanna,
Chief Operating Officer -
Corinne Pankovcin,
Chief Financial Officer -
Dr. Joachim-Friedrich Kapp M.D., Ph.D.,
Sr. VP of Clinical Devel. - Autoimmunity -
Dr. Dolly B. Tyan Ph.D.,
Sr. VP of Clinical Devel. Â Transplantation -
Jennifer Lee,
Director of HR -
Matthew M. Shatzkes,
Chief Legal Officer & Gen. Counsel -
Rowena Albanna,
Chief Operating Officer -
Thomas J. Farley CPA,
Chief Financial Officer -
Lauren Chung,
Director -
Charles Athle Nelson,
Director -
Thomas J Farley,
Chief Financial Officer -
Paribas Securities Corp Bnp,